Cetuximab plus chemotherapy for advanced gastric cancer (GC) shows an active result in phase 2 trials. Unfortunately, Combination of cetuximab does not provide enough benefit to chemotherapy alone in phase 3 trials. Studies have demonstrated that berberine can suppress the activation of EGFR in tumors. In this study, we evaluated whether berberine could enhance the effects of EGFR-TKIs in GC cell lines and xenograft models. Our data suggest that berberine could effectively enhance the activity of erlotinib and cetuximab in vitro and in vivo. Berberine was found to inhibit growth in GC cell lines and to induce apoptosis. These effects were linked to inhibition of EGFR signaling activation, including the phosphorylation of STAT3. The expressions of Bcl-xL and Cyclind1 proteins were decreased, whereas the levels of cleavage of poly-ADP ribose polymerase (PARP) were considerably increased in the cell lines in response to berberine treatment. These results suggest a potential role for berberine in the treatment of GC, particularly in combination with EGFR-TKIs therapy. Berberine may be a competent therapeutic agent in GC where it can enhance the effects of EGFR inhibitors.
INTRODUCTION
Berberine is a natural component derived from Ranunculaceae and Papaveraceae families of plants. Berberine is a commonly used and well-tolerated drug for gastrointestinal disorders [1] . A lot of previous studies have revealed the anti-tumor potential of berberine against various types of human cancer cell lines and xenograft models [2] . In several cancer models, berberine has been proven to stimulate apoptosis, suppress cancer cell growth and arrest cell cycle [3, 4] . Studies also stressed the actions of berberine in inhibiting tumor cell invasion and angiogenesis [5, 6] . The molecular targets of berberine's antitumor activity include p53, AKT, MAPK, STAT3 and NFκB, which can monitor the cell cycle, apoptosis, tumor angiogenesis, and invasion [7] . Berberine also suppresses the activation of some cell growth factor receptors such as EGFR, ERBB2, and VEGF [8] .
In spite of the decline in the incidence and mortality of gastric cancer in recent years, the 5-year survival rate of patients with gastric cancer remains relatively low [9] . EGFR, one of the ErbB family of receptors, is overexpressed in gastric cancers, and is related to older age, more aggressive histology and higher disease stage. EGFR expression is correlated with poor clinical outcome in gastric cancer [10, 11] . Cetuximab, an antibody that targets the EGFR, and erlotinib, an EGFR-targeting small molecule tyrosine kinase inhibitor (TKI) are currently under clinical evaluation in gastric cancer trials. However, combination of cetuximab with chemotherapy produced unsatisfactory results for gastric cancer. The PFS and Research Paper www.impactjournals.com/oncotarget overall survival in the combination therapy are much lower than expected [12] .
Berberine-induced inhibition of EGFR has recently been declared in human colon tumor, prostate cancer and human glioblastoma cells [13, 14, 15] . In the current study, we hypothesize that berberine can be used to target EGFR signaling and may enhance the effects of cetuximab or erlotinib.
RESULTS

Berberine inhibits cell viability in GC cell lines and decreases the phosphorylation of EGFR
Three GC cell lines, MKN45, BGC823 and SGC7901, were treated for 24,48,72 hours with berberine at concentrations ranging from 15μM to 90μM, and compared to the vehicle (DMSO) alone. Berberine resulted in the decrease of the number of viable MKN45, BGC823 and SGC7901 cells in concentration dependent manners ( Figure 1A ). MKN45, BGC823 and SGC7901 were EGFR-positive gastric cancer cells ( Figure 1B ). After 24 hour berberine treatment, we found that phosphorylated EGFR levels decreased and EGFR overall expression levels remained unchanged ( Figure 1C, 1D ). When gastric cancer cells were treated with berberine(72h IC50) for 72 hours, the level of phosphorylation of EGFR also decline, but EGFR remained unaffected ( Figure 1E ). It suggests that berberine likely affects EGFR activation.
Berberine enhances the activity of erlotinib and cetuximab in gastric cells
Berberine was tested for its ability to enhance the antitumor effects of EGFR inhibitors in gastric cancer. We used erlotinib and cetuximab in SGC7901, BGC823 cell culture experiments by MTT assays. Berberine enhanced the growth inhibition seen with erlotinib ( Figure 2A , 2B, 2C) or cetuximab ( Figure 2D , 2E, 2F) treatment in vitro. Combining berberine at its IC50 in treatment of SGC7901 cells (48 μM) with the approximate IC50 for erlotinib (30 μM) resulted in a 80.5% growth inhibition, compared to 52% growth inhibition for erlotinib alone, a 1.5-fold enhancement, The median effect analysis showed that the combination index (CI) was smaller than 1 ( Figure 2G , 2H), indicating the synergism between berberine and cetuximab or erlotinib.
Berberine and erlotinib synergistically enhanced apoptosis and cell cycle arrest in gastric cells
We next analyzed the induction of apoptosis and cell cycle in BGC823 cells treated with berberine alone or in combination with erlotinib. Flow cytometric analysis revealed that berberine alone induced the apoptosis and cell cycle arrest of BGC823 cells, and the combination therapy further augmented this effect ( Figure 3A, 3B) .
Taken together, these in vitro data suggest that the combined use of berberine enhances the activity of erlotinib and cetuximab in gastric cancer cells.
Berberine inhibits EGFR signaling pathway
Berberine inhibits EGFR downstream molecules such as:STAT3, AKT, ERK, NFκB, as well as declines in expression of Bcl-xL and cyclinD1, which regulate apoptosis and cell cycle, respectively ( Figure 4A, 4B) . These data indicate that by inhibiting both EGFR and downstream AKT, ERK, STAT3 activation, berberine may have potential utility in the treatment of gastric cancer.
We detected that berberine inhibited EGFR signaling pathway and downstream targets Bcl-xL and cyclinD1. Then this inhibitory effect of berberine was weakened when cells were pretreated with EGF. Combining berberine with erlotinib, inhibitory effect was amplified ( Figure 4C ). Furthermore, siRNAs for STAT3 were synthesized and their inhibitory effects on STAT3 were confirmed by western blotting. Remarkably, silencing of STAT3 in BGC823 cells decreased Bcl-xL and cyclinD1 protein expression, and also increased apoptosis marker cleaved PARP ( Figure 4D ).
These data suggested that berberine inhibited the phosphorylation of EGFR may regulate Bcl-xL and cyclinD1expression via STAT3.
Berberine enhances the growth inhibitory activity of cetuximab and inhibits EGFR signaling in vivo
In order to assess whether berberine could enhance the anticancer activity of EGFR inhibitors in vivo, as was seen in vitro, female nude mice were inoculated with BGC823 cells. After tumor outgrowth and randomization to treatment groups, mice were treated with vehicle, cetuximab alone, berberine alone, or berberine plus cetuximab on alternating days. Berberine was found to significantly enhance the growth inhibitory activity of cetuximab. Treatment with cetuximab slightly slowed down the tumor growth in xenografts. Berberine alone resulted in xenograft shrinkage significantly. Importantly, combination berberine with cetuximab further reduced the tumor size in this model. After 4 weeks the animals were sacrificed, the combination therapy caused a 66% decrease in tumor volume as compared with the control group, whereas cetuximab alone and berberine alone caused a 32%, 55% decrease respectively ( Figure 5A ). Similarly, the combination therapy showed significantly decreased tumor weight ( Figure 5B and 5C). During the experiments, no obvious weight loss was observed in mice treated with berberine, cetuximab, or both ( Figure 5D ). www.impactjournals.com/oncotarget
To validate why combination of berberine and cetuximab is more effective than either drug alone, we next analyzed EGFR/STAT3signaling pathway in xenografts. Immunohistochemistry showed high expression of p-EGFR and Ki67, low apoptotic bodies in the control. Berberine treatment alone or in combination with cetuximab increased apoptotic bodies and decreased p-EGFR and Ki67 expression ( Figure 6A ). Western blotting showed that decreased levels of tyrosine phosphorylated STAT3, Bcl-Xl and cyclin D1 in mice treated with cetuximab plus berberine compared to the control and cetuximab alone (Figures 6B).
Berberine suppresses phosphorylation of receptor tyrosine kinases in GC cell lines
We revealed that berberine inhibited EGFR signaling pathway in gastric cancer. To correlate the berberine to other tyrosine kinases activity, PhosphoTyrosine (P-Tyr-1000) MultiMab™ Rabbit mAb mix and shown. * P < 0.05 compared with control. ** P < 0.01compared with control. B. EGFR expression in GC cell lines measured by immunoblot, β-actin was used as a loading control. C. Immunofluorescence staining showed that GC cell lines with berberine treatment expressed low levels of phosphorylation of EGFR. The nucleus was stained with 40,6-diamidino-2-phenylindole in the merged images. Scale bars: 30 um. D. Cells were treated with different concentrations of berberine for 24 h, and the expression levels of total EGFR and phosphorylation of EGFR were detected by Western blotting. β-actin was used as a loading control. E. Cells were treated with berberine (72h IC50) for indicated time. The expression of proteins was evaluated by Western blotting. Representative of three independent experiments was shown. β-actin was used as a loading control. BBR, berberine, DAPI, 40, 6-diamidino-2-phenylindole.
PathScan RTK Signaling Antibody Array kit were used (Figure 7) . MKN45, BGC823 and SGC7901 cells were stimulated with berberine, or were treated with DMSO. After normalization to the negative control, we found that most of tyrosine kinase obtained lower phosphorylation signal in berberine group than DMSO group such as EGFR, ERBB2, FGFR1, MET, VEGFR2. These tyrosine antibody data suggest a possible signaling pathway regulated through the cell growth factor receptors pathway. Simultaneously, phosphorylation signals of ERK, SRC and STAT3 also reduced.
DISCUSSION
EGFR is overexpressed in gastric cancers [16] . Phase 2 studies assessed the efficacy of cetuximab combined with chemotherapy for advanced gastric cancer.
The results is active and drug toxicity is acceptable [17, 18] . However, in phase 3 trials additions of cetuximab to capecitabine-cisplatin don't provide additional benefit to chemotherapy alone in advanced gastric cancer [19] . Thus, novel strategies are an urgent need to enhance the effects of EGFR-TKIs in GC. In the current study, we investigated berberine's potential utility in the treatment of GC. Berberine was found to inhibit growth and induce apoptosis. Simultaneously, berberine effectively improved the antitumor effects of erlotinib and cetuximab on GC cell lines in vitro and in vivo.
It has been reported that berberine could suppress the constitutive activation of EGFR in human colon tumor, prostate cancer and glioblastoma [13, 14, 15] . Berberine has been proven to inhibit EGFR through activation of Cbl in colon tumor cells [13] . More recently, berberine downregulate the EGFR-MEK-ERK signaling pathway in human glioblastoma cells [15] . Furthermore, EGFR was inhibited in berberine treatment of prostate cancer cell lines [14] . In our study, berberine was found to decrease phosphorylation levels of EGFR both in vitro and in vivo. Berberine resulted in decreased levels of pERK, pAKT, pNFκB and pSTAT3, as well, suggesting global inhibition of the EGFR signaling pathway.
The dose of berberine we used in vivo experiments is just the same as used in gastroenteritis patients. Rats treated with berberine at a dose of 156 mg/kg/day for 90 days show no abnormality in clinical signs, body weights, organ weights, urinalysis, hematological parameters, gross necropsy and histopathology [20] . And in our experiment, mice received only dose of 50 mg/kg at daily diet. During the experiments, no obvious weight loss was observed in mice treated with berberine, cetuximab, or both. By Reagan-Shaw method [21] , The human equivalent of the murine dose of 50 mg/kg is 250 mg in an adult of 60kg. The standard dose of berberine is 900-2,000 mg a day. Thus, the dose of breberine in our study is within a therapeutic range in humans.
Interestingly, EGFR-TKIs treatment resulted in AKT and NFκB activation in detected GC cell lines and maintenance activation of PI3K/AKT pathway signaling was associated with therapeutic resistance to EGFR-TKIs. It has been verified that AKT signaling is associated with the berberine treatment of GC cells [22] . So we silenced STAT3 and inhibited phosphorylation of ERK in BGC823 cells. Silencing STAT3 decreased Bcl-xL, cyclinD1 and increased cleaved PARP. However, ERK inactivation did not show similar results. Thus, our data provided evidence that berberine enhanced the antitumor effects of EGFR-TKI therapies by inhibiting EGFR/STAT3 signaling pathways.
It was reported recently that amplification of MET, FGFR1 and ERBB2 was involved in EGFR therapeutic resistance in colorectal cancer [23] . If these findings can be translated into gastric cancer settings, patients with high expression of MET, FGFR1 and ERBB2 may exhibit EGFR therapeutic resistance. Tissue microarray analyzed that HER2, EGFR, MET and FGFR2 predominances were respectively observed in 10.1, 13.9, 16.1 and 22.9% of the gastric adenocarcinomas. Nearly two-thirds of GC patients exhibited at least one RTK. Moreover, one-third of cases showed multiple RTKs expressions [24] . Thus, resistance of EGFR targeting therapies may be due to activation of alternative signaling pathways, including ERBB2, cMET or FGFR receptors. In this study, RTK Signaling antibody array showed that berberine could reduce phosphorylation levels of EGFR, ERBB2, FGFR1, cMET, VEGFR2 at the same time. Our results suggest berberine may potentially be useful in overcoming the resistance to EGFR targeting agents.
In addition, cetuximab combined with chemotherapy shows a serious side effect diarrhea [25] . Fortunately, berberine has become therapeutics for the treatment of diarrhea and gastroenteritis. It is used in the treatment of diarrhea of different origins [26, 27] . Accordingly, berberine combined with EGFR inhibitors to GC patients may be more effective and safer, because this combination treatment may not only increase EGFR-TKIs efficacy, but also prevent or alleviate the diarrhea symptom.
Therefore, administration of a compound that enhances the activity of GC treatment may be a useful complementary strategy. In this study, we have proven that berberine enhanced the activity of erlotinib and cetuximab in vitro and in vivo by inhibiting the EGFR/ STAT3 signaling pathway, which suggests a potential role for berberine in the treatment of GC, particularly in combination with EGFR-TKIs therapy.
MATERIALS AND METHODS
Reagents and cells
Gastric cancer cell linesMKN45, BGC823, SGC7901, were maintained in RPMI-1640 medium (HyClone, Logan, UT, USA) with 10% fetal bovine serum (FBS) at 37°C in a humidified air atmosphere containing 5% CO2. Berberine chloride hydrate, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Antibodies specific to EGFR, pEGFR, ERK, pERK (Thr202/Tyr204), AKT, pAKT, STAT3, pSTAT3, NFκB, pNFκB, Bcl-xL, Cleaved PARP, Cyclin D1 and Phospho-Tyrosine (P-Tyr-1000) MultiMab™ Rabbit mAb mix were purchased from Cell Signaling Technology Inc. (Beverly, MA). Antibody against actin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Erlotinib and U0126(ERK inhibitor) was purchased from Cell Signaling Technology Inc. (Beverly, MA). Cetuximab was purchased from Merck Lyon Pharmaceutical Company Limited (GER).
PathScan RTK antibody array kit
The PathScan RTK signaling array kit(Cell Signaling Technologies) contains fixed antibodies against phosphorylated forms of kinases and key signaling proteins. The kit includes 28 receptor tyrosine kinases and 11 important signaling nodes. It was used according to the manufacturer's instructions. Images were analyzed by ImageJ (http://rsbweb.nih.gov/ij/) 
Cell viability assay
Cell viability was detected using the MTT assay. Cells were cultured in triplicate in 96-well plates and treated with increasing concentrations of with berberine, erlotinib, cetuximab or the corresponding vehicles. After 48 hours, cell growth was measured by 0.5 mg/ml MTT. Cell viability was expressed as a percentage of control. The IC50 was calculated using Prism software version 4.03 (GraphPad Software Inc).
Calculation of synergism
The medium-effect method was used to evaluate dose-response data for multiple drugs. The Chou and Talalay [28] combination index (CI), a well-established index reflecting the interaction of two drugs, was calculated at different levels of growth inhibition with the use of software package Calcusyn (Biosoft, Cambridge, UK). The CI for 50% growth inhibition (IC50) was calculated as follows: CI values of <1, 1, and >1 indicate synergistic, additive, and antagonistic effects, respectively.
Apoptosis assay
Cell apoptosis was assessed using an Annexin-V-FITC apoptosis detection kit (BD, Franklin Lakes, NJ, USA) as previously described [29] .
Western blotting
Following treatment with specific drugs, total cell lysates are prepared and subjected to SDS-PAGE using 8%, 10% or 12% running gels. Western blotting was done as previously described [30] .
In vivo tumor xenograft study
Female five-week-old BALB/C-nu/nu nude mice are obtained from the Shanghai Laboratory. The animal study protocols were approved by institutional animal care and use committee. BGC823 cells (2×10 6 per mouse) were subcutaneously injected into the flank of each mouse. After outgrowth of palpable tumors, mice were randomized, by tumor volume, to 4 treatment groups. The cetuximab treatment group received 0.8 mg/mouse/ day, by intraperitoneal injection, twice per week. The combination treatment group received both cetuximab, twice per week, and berberine. Berberine was dissolved in carboxymethylcellulose sodium for use in oral gavage (50 mg/kg body weight) daily. Tumors were measured using digital calipers twice per week and tumor volumes calculated using the following formula: Volume= L × (W) 2 /2 (L: longest diameter; W: shorter diameter). At the end of the study, mice were euthanized and tumor tissues harvested and frozen for analysis.
Immunohistochemistry
The immunohistochemical staining of p-EGFR, Ki67 and TUNEL was performed as previously described [31] . Target protein expression was evaluated according to the ratio of positive cells per specimen, and staining intensity was determined according to a histological scoring method.
Statistical analyses
The data were presented as the means ± standard errors of the mean (SEM) or medians (ranges). Student's t-test (two-tailed) or an one-way ANOVA test was employed to analyze the in vitro and in vivo data unless otherwise indicated (χ2 test). The non-parametric MannWhitney test was used to analyze the relationship between p-EGFR expression levels and various clinicopathologic characteristics. Statistical tests were performed using SPSS 17.0 software (Chicago, IL, USA). P < 0.05 was defined as statistically significant.
